Ferumoxytol as an Intravenous Iron Replacement Therapy in Hemodialysis Patients
Open Access
- 1 February 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of the American Society of Nephrology
- Vol. 4 (2), 386-393
- https://doi.org/10.2215/cjn.02840608
Abstract
Background and objectives: Intravenous iron is a key component of anemia management for chronic kidney disease (CKD). Ferumoxytol is a unique intravenous iron product that can be administered as a rapid injection in doses up to 510 mg. Design, setting, participants, & measurements: This was a randomized, open-label, controlled, multicenter Phase 3 trial to evaluate the safety and efficacy of intravenous ferumoxytol compared with oral iron. Anemic patients with CKD stage 5D on hemodialysis and on a stable erythropoiesis-stimulating agent regimen received either two injections of 510 mg of ferumoxytol within 7 d (n = 114) or 200 mg elemental oral iron daily for 21 d (n = 116). The primary efficacy endpoint was the change in hemoglobin from baseline to day 35. Safety was closely monitored. Results: Ferumoxytol resulted in a mean increase in hemoglobin of 1.02 ± 1.13 g/dl at day 35 compared with 0.46 ± 1.06 g/dl with oral iron (P = 0.0002). Twice as many ferumoxytol-treated patients than oral iron-treated patients achieved a ≥1 g/dl hemoglobin increase at day 35 (P = 0.0002). There was a greater mean increase in transferrin saturation (TSAT) with ferumoxytol compared with oral iron at day 35 (P < 0.0001). The larger hemoglobin increase after ferumoxytol compared with oral iron at day 35 persisted after adjustment for baseline hemoglobin, TSAT, and serum ferritin. Overall adverse event rates were comparable between groups. Conclusions: In patients on hemodialysis, rapid intravenous injection of 510 mg of ferumoxytol led to significantly greater hemoglobin increases compared with oral iron, with comparable tolerability.Keywords
This publication has 30 references indexed in Scilit:
- Safety of Ferumoxytol in Patients With Anemia and CKDAmerican Journal of Kidney Diseases, 2008
- Ferumoxytol for Treating Iron Deficiency Anemia in CKDJournal of the American Society of Nephrology, 2008
- Ferric Gluconate Reduces Epoetin Requirements in Hemodialysis Patients with Elevated FerritinJournal of the American Society of Nephrology, 2008
- Role of Oral Iron in the Management of Long-Term Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2007
- Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin SaturationJournal of the American Society of Nephrology, 2007
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseThe New England Journal of Medicine, 2006
- II. Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease in AdultsAmerican Journal of Kidney Diseases, 2006
- CPG and CPR 3.2. Using Iron AgentsAmerican Journal of Kidney Diseases, 2006
- The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patientsKidney International, 2005
- Pharmacokinetic Study of Ferumoxytol: A New Iron Replacement Therapy in Normal Subjects and Hemodialysis PatientsAmerican Journal of Nephrology, 2005